New test to identify heart failure in ER superior

NEW ORLEANS (Reuters) - A new blood test to identify heart failure patients in most dire need of treatment when they turn up at an emergency room complaining of shortness of breath proved better than current tests, according to results of a study unveiled on Tuesday.

The pivotal trial of the test developed by privately held German company Brahms AG succeeded in its goal of demonstrating superiority over tests considered the current gold standard.

“I think that this is clearly significantly better than what we have now,” Dr. W. Frank Peacock of the Cleveland Clinic, one of the study’s lead investigators, said in an interview. “It raises the bar.”

The Brahms test was approved for use in Europe on October 1. Nils Morgenthaler, the company’s vice president for global medical affairs, said this study would be part of a package Brahms will submit to the U.S. Food and Drug Administration by the end of this year as it seeks approval in the world’s biggest market.

“If approved in the U.S., the MR-proADM test will help ensure patients are accurately diagnosed and rapidly receive the treatment they need,” Peacock said.

Results of the study were presented at the American Heart Association scientific meeting in New Orleans.

Morgenthaler said the company would be open to licensing its test to one of the larger diagnostic companies, such as Roche Holding AG. He also said Brahms was likely to become a public company in the foreseeable future.

(Reporting by Bill Berkrot; Editing by Lisa Von Ahn)


Related Posts:

BOSTON (Reuters) - Quest Diagnostics Inc said on Thursday that it had provided possibly erroneous results to thousands of people who had their vitamin D levels tested over the past two years. Quest, the largest U.S. provider of diagnostic testing, said it sent letters to doctors who might have received “questionable” test results. Dr. Wael Salameh, Quest’s

Full Post: Quest says some vitamin D tests gave wrong result

By Michael Kahn LONDON (Reuters) - People taking NeuroSearch A/S’s obesity pill tesofensine lost twice as much weight as men and women using approved weight loss drugs, Danish researchers said on Thursday. The study suggest the experimental drug is safe because it had no effect on blood pressure and only raised heart rate slightly, said Arne Astrup

Full Post: Obesity pill shows promise: study

By Bill Berkrot and Ransdell Pierson NEW ORLEANS (Reuters) - AstraZeneca’s cholesterol fighter Crestor dramatically cut deaths, heart attacks and strokes in patients with healthy cholesterol levels but who had high levels of a protein associated with heart disease, researchers said on Sunday. Crestor, known chemically as rosuvastatin, reduced heart attack, stroke, need for bypass or angioplasty

Full Post: AstraZeneca’s Crestor cuts deaths and heart attacks

WASHINGTON (Reuters) - U.S. health regulators have approved Novartis’ drug Gleevac to reduce the risk of cancer recurring in patients with a rare type of stomach cancer, Novartis said on Friday. Gleevac is already approved by the Food and Drug Administration to treat gastrointestinal stromal tumor, a severe type of cancer that recurs in as many

Full Post: U.S. OKs Novartis Gleevac to reduce recurring cancer

By Bill Berkrot and Ransdell Pierson NEW ORLEANS (Reuters) - Sanofi-Aventis’s experimental drug Multaq significantly reduced the incidence of hospitalization and length of hospital stays in patients with atrial fibrillation, according to a new analysis of a previously reported study, researchers said on Tuesday. Multaq, known chemically as dronedarone, cut the total number of hospital days by

Full Post: Sanofi’s Multaq reduces hospitalization: study

Site Navigation

Most Read